These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23828409)

  • 21. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.
    Kao SC; Kirschner MB; Cooper WA; Tran T; Burgers S; Wright C; Korse T; van den Broek D; Edelman J; Vallely M; McCaughan B; Pavlakis N; Clarke S; Molloy MP; van Zandwijk N; Reid G
    Br J Cancer; 2016 Mar; 114(5):524-31. PubMed ID: 26889976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pleural neoplastic pathology.
    Karpathiou G; Stefanou D; Froudarakis ME
    Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
    PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
    Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
    Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway.
    Goudarzi H; Iizasa H; Furuhashi M; Nakazawa S; Nakane R; Liang S; Hida Y; Yanagihara K; Kubo T; Nakagawa K; Kobayashi M; Irimura T; Hamada J
    Cancer Lett; 2013 Oct; 339(1):82-92. PubMed ID: 23879962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E
    Lung Cancer; 2016 Jun; 96():1-6. PubMed ID: 27133741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
    Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
    Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN
    Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
    Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
    Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of plakophilin 3 in diffuse malignant pleural mesothelioma.
    Mašić S; Brčić L; Krušlin B; Šepac A; Pigac B; Stančić-Rokotov D; Jakopović M; Seiwerth S
    Histol Histopathol; 2018 Sep; 33(9):995-1004. PubMed ID: 29722422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
    Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
    Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
    J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.
    Rrapaj E; Trisolini E; Bertero L; Salvo M; Indellicato R; Andorno S; Garcia-Manteiga JM; Rena O; Boldorini RL
    Histopathology; 2018 May; 72(6):1039-1050. PubMed ID: 29356044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.